Destiny Hinton
Destiny Hinton is a communications intern in the Department of Communications & Scientific and Medical Content Outreach at St. Jude Children’s Research Hospital.
Stories by Destiny Hinton
It’s in the genes: research reveals obstacles on the road to health for cancer survivors
St. Jude scientists are leading research into the genetics of childhood cancer survivorship to understand and prevent the risk of chronic disease in survivors.
Two Years of the Pediatric Translational Neuroscience Initiative
St. Jude initiative aims to change the outlook for children with catastrophic neurological diseases.
What Parents and Caregivers Should Know about HPV Vaccination
Now is a great time for kids to get vaccinated against HPV and protected against six different cancers.
Expanding the St. Jude strategic plan to $12.9 billion helps further advance its mission
Dr. James R. Downing details how St. Jude strategic plan expansion aims to accelerate research and treatment for childhood catastrophic diseases.
T cells are key to maintaining cancer remissions from chemotherapy
Stimulating the adaptive immune response can improve outcomes for ALL treated with chemotherapy.
St. Jude researchers answer COVID questions
St. Jude research has advanced understanding of the immune response to SARS-CoV-2 infection and vaccination. Here is what the findings mean for you.
Take the prevent HPV pledge and let’s stop cancer before it starts
HPV vaccination rates dipped during the COVID-19 pandemic. St. Jude is working with more than 100 organizations, health experts and others to highlight vaccination as cancer prevention.
SAFER Ukraine: a framework for responding to global conflicts
What lessons can be learned from the remarkable success of SAFER Ukraine?
Research points to a way to reduce cachexia, a cancer-induced muscle wasting disorder
Muscle signaling provide clues for treatment of the muscle-wasting disorder cachexia, which affects cancer patients.
Five years later: gene therapy for ‘bubble boy’ disease
Interim results point to enduring immune function following gene therapy for Infants with ‘bubble boy’ disease